GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (STU:2LB) » Definitions » Shiller PE Ratio

Iovance Biotherapeutics (STU:2LB) Shiller PE Ratio : (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Iovance Biotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Iovance Biotherapeutics Shiller PE Ratio Historical Data

The historical data trend for Iovance Biotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Shiller PE Ratio Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Iovance Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Iovance Biotherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Iovance Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Shiller PE Ratio falls into.



Iovance Biotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Iovance Biotherapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Iovance Biotherapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.252/133.0289*133.0289
=-0.252

Current CPI (Sep. 2024) = 133.0289.

Iovance Biotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.146 99.070 -0.196
201503 -0.129 99.621 -0.172
201506 -0.125 100.684 -0.165
201509 -0.143 100.392 -0.189
201512 -0.184 99.792 -0.245
201603 -0.126 100.470 -0.167
201606 -0.205 101.688 -0.268
201609 -1.025 101.861 -1.339
201612 -0.237 101.863 -0.310
201703 -0.309 102.862 -0.400
201706 -0.329 103.349 -0.423
201709 -0.294 104.136 -0.376
201712 -0.304 104.011 -0.389
201803 -0.251 105.290 -0.317
201806 -0.291 106.317 -0.364
201809 -0.309 106.507 -0.386
201812 -0.237 105.998 -0.297
201903 -0.266 107.251 -0.330
201906 -0.336 108.070 -0.414
201909 -0.363 108.329 -0.446
201912 -0.450 108.420 -0.552
202003 -0.498 108.902 -0.608
202006 -0.417 108.767 -0.510
202009 -0.340 109.815 -0.412
202012 -0.386 109.897 -0.467
202103 -0.428 111.754 -0.509
202106 -0.440 114.631 -0.511
202109 -0.468 115.734 -0.538
202112 -0.558 117.630 -0.631
202203 -0.527 121.301 -0.578
202206 -0.596 125.017 -0.634
202209 -0.636 125.227 -0.676
202212 -0.604 125.222 -0.642
202303 -0.467 127.348 -0.488
202306 -0.434 128.729 -0.448
202309 -0.431 129.860 -0.442
202312 -0.413 129.419 -0.425
202403 -0.386 131.776 -0.390
202406 -0.316 132.554 -0.317
202409 -0.252 133.029 -0.252

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Iovance Biotherapeutics  (STU:2LB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Iovance Biotherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines